Skip to main
  1. Stocks
  2. AbbVie
  3. Forecast
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 32%
Buy 50%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is viewed positively because its core immunology franchise remains exceptionally durable, with Skyrizi and Rinvoq delivering strong TRx growth and expected top-line beats that can offset Humira’s decline. The firm also benefits from a diversified, capital-efficient portfolio that was broadened by the 2020 Allergan deal and further strengthened in 2024 through Cerevel and ImmunoGen, while oncology and neuroscience provide additional upside. With no meaningful LOEs this decade, strong cash generation, a 3% dividend, and about $10-15bn of M&A capacity, its predictable double-digit EPS growth supports a premium fundamental outlook.

Bears say

AbbVie is facing a deteriorating fundamental profile as its base business growth weakens, operating margins come under pressure, and EPS growth slows, while valuation risk rises if the P/E multiple contracts to 13x. Competitive threats in immunology could erode Skyrizi and Rinvoq share, and disappointing clinical data, regulatory setbacks, or patent challenges would further undermine confidence in the portfolio. The 2020 Allergan deal and the 2024 Cerevel and ImmunoGen acquisitions broaden the platform, but integration risk, pricing فشار, and Aesthetics exposure at about 8% of FY 2025 sales leave the company vulnerable in a more defensive outlook.

AbbVie (ABBV) has been analyzed by 22 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 50% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

AbbVie (ABBV) Analyst Forecast & Price Prediction

Get the latest AbbVie (ABBV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AbbVie (ABBV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 22 analysts, AbbVie (ABBV) has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $288.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $288.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


AbbVie (ABBV) Analyst Forecast & Price Prediction

Get the latest AbbVie (ABBV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AbbVie (ABBV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ABBV stock data and trends